Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2025 Apr 25.
Published in final edited form as: Biochemistry. 2024 Apr 15;63(9):1067–1074. doi: 10.1021/acs.biochem.4c00056

Stereospecific NANOG PEST Stabilization by Pin1

Josephine C Ferreon 1,*, Hai Minh Ta 2, Hyosuk Yun 3, Kyoung-Jae Choi 4, My Diem Quan 5, Phoebe S Tsoi 6, Choel Kim 7, Chul Won Lee 8,*, Allan Chris M Ferreon 9,*
PMCID: PMC12022813  NIHMSID: NIHMS2072181  PMID: 38619104

Abstract

NANOG protein levels correlate with stem cell pluripotency. NANOG concentrations fluctuate constantly with low NANOG levels leading to spontaneous cell differentiation. Previous literature implicated Pin1, a phosphorylation-dependent prolyl isomerase, as a key player in NANOG stabilization. Here, using NMR spectroscopy, we investigate the molecular interactions of Pin1 with the NANOG unstructured N-terminal domain that contains a PEST sequence with two phosphorylation sites. Phosphorylation of NANOG PEST peptides increases affinity to Pin1. By systematically increasing the amount of cis PEST conformers, we show that the peptides bind tighter to the prolyl isomerase domain (PPIase) of Pin1. Phosphorylation and cis Pro enhancement at both PEST sites lead to a 5–10-fold increase in NANOG binding to the Pin1 WW domain and PPIase domain, respectively. The cis-populated NANOG PEST peptides can be potential inhibitors for disrupting Pin1-dependent NANOG stabilization in cancer stem cells.


NANOG is a critical marker for stem cell pluripotency.1,2 Regulated by master transcription factors such as OCT4, SOX2, and KLF4,3,4 NANOG levels are in constant flux, allowing cells transient windows of opportunity for differentiation.1,2 We have previously shown that NANOG oligomerization via its prion-like C-terminal domain plays a critical role in NANOG stabilization and in establishing stem cell pluripotency.5 Phosphorylation can be another mechanism of regulating NANOG stability.6-8 NANOG has a PEST motif9 in the N-terminal domain (NTD, Figure 1) that targets NANOG for ubiquitination and proteasomal degradation.8 Within this PEST sequence are phosphorylation sites for proline-directed kinases such as ERK1/2 and CDKs.6,7,10 Pin1 is a phosphorylation-dependent cistrans prolyl isomerase that acts on substrates involved in cell signaling, cell cycle control, and proliferation.11-27 In embryonic stem cells (ESCs), Pin1 interacts with NANOG to suppress its ubiquitination and degradation.6 Disruption of Pin1-NANOG interaction inhibits ESC self-renewal potential.6

Figure 1.

Figure 1.

NANOG NTD PEST phosphorylation. (a) NANOG disorder profile. Rapid Intrinsic Disorder Analysis Online (RIDAO) plots a disorder score per residue with scores >0.5 predicted to be disordered while residues with scores <0.5 are predicted to be ordered. RIDAO28 incorporates disorder predictors PONDRs VLXT,49 VL3,50 and VSL2,51 as well as IUPred-Long,52 IUPred-Short,52 and PONDR-FIT.53 MDP (gray area) represents the mean disorder profile. (b) NANOG structure prediction by Alphafold.29,30 (c) Domain organization of NANOG (NTD, N-terminal domain; DBD, DNA-binding domain; WR, tryptophan repeat domain). Protein sequence of NANOG NTD residues 49–74 showing the PEST sequence (highlighted in green) and the phosphorylation sites by p38d kinase (red). (d) Superimposition of the 2D NMR 15N-HSQC spectra of unphosphorylated (green) and phosphorylated (red) 15N NANOG NTD(49–74). Arrows indicate the chemical shift changes upon phosphorylation. The minor peaks are due to minor cis populations associated with proline isomerization (e.g., pS52′ is a minor cis population).

Results and Discussion.

Our previous work has shown that human NANOG (Uniprot ID: Q9H9S0) is a predominantly intrinsically disordered protein with a structured DNA-binding domain and unstructured N-terminal and C-terminal domains.5 The experimental data are consistent with disorder and structural predictions by RIDAO28 and Alphafold29,30 (Figure 1a,b). To gain insights into the NANOG NTD PEST structure, we collected triple resonance NMR data using the NANOG NTD(49–74) construct (Figure 1c,d), and we determined the HN, N, Cα, and Cβ chemical shifts. The assigned NMR chemical shifts approximated random coil values31 (Table 1), suggesting that NANOG NTD(49–74) is unstructured. To investigate the effect of phosphorylation, we prepared in vitro phosphorylated NANOG NTD(49–74) using p38δ kinase. Phosphorylation of NANOG NTD resulted in large chemical shift changes (~1–2 ppm of Cβ, ~0.3–0.5 ppm of HN) for the phosphorylated serine residues, pS52, pS65, and pS71 (Table 1, Figure 1d). Aside from the serine residues, most of the residues display chemical shifts close to those of unphosphorylated peptide, suggesting that phosphorylation did not alter the disordered nature of the NANOG PEST sequence. Our data confirm previous mass spectrometry data7 that the NANOG PEST sequence can be phosphorylated by proline-directed kinases.

Table 1.

NMR Chemical Shifts of Unphosphorylated and Phosphorylated NANOG NTD (49–74; BMRB IDs 52388 and 52389, Respectively)a

Nan NTD (49-74) Phos Nan NTD(49-74)
Res. No. Res CA CB N HN CA CB N HN
49 E 56.49 30.45 56.75 30.29
50 T 62.08 69.87 116.9 8.388 61.71 69.97 115.9 8.288
51 V 62.18 32.85 123.6 8.279 61.91 33.02 122.8 8.245
52 S 56.32 63.39 121.7 8.458 55.84 65.39 122.4 8.702
53 P 62.06 32.89 62.92 32.15
54 L 53.1 41.67 123.7 8.284 53.18 41.61 123.9 8.352
55 P 63.23 32.05 63.23 32.05
56 S 58.42 64.01 115.9 8.418 58.42 64.01 115.9 8.415
57 S 58.69 63.73 117.5 8.328 58.62 63.82 117.6 8.333
58 M 55.92 32.66 121.7 8.302 55.75 32.83 122 8.275
59 D 54.79 40.95 120.9 8.164 54.59 40.95 121.4 8.248
60 L 55.32 42.18 121.7 7.979 55.29 42.36 121.8 7.998
61 L 55.32 42.18 122.6 8.1 55.29 42.12 122.8 8.117
62 I 61.14 38.43 122.2 8.02 61.09 38.45 122.4 8.043
63 Q 55.76 29.8 124.6 8.393 55.65 29.83 124.9 8.411
64 D 54.43 41.26 122.1 8.364 54.45 41.32 122.3 8.376
65 S 55.55 64.56 118.5 7.998 55.4 65.85 117.1 8.541
66 P 63.62 31.99 63.51 32.11
67 D 54.47 41.19 119.7 8.326 54.46 41.13 120.1 8.35
68 S 58.75 63.77 116.7 8.249 58.59 63.85 116.6 8.228
69 S 59.02 63.74 117.8 8.414 58.64 64.02 117.9 8.4
70 T 61.79 69.67 114.8 8.075 61.75 69.79 115.3 8.193
71 S 56.61 63.25 119.5 8.155 55.71 65.27 119.8 8.49
72 P 63.42 32.11 63.6 32.06
73 K 56.21 33.2 122.1 8.435 55.72 33.22 122.5 8.489
74 G 46.12 116.3 7.952 46.12 116.2 7.997
a

Phosphorylated serine residues are highlighted in red. Proline residues are shaded in gray.

To systematically characterize the role of phosphorylation in Pin1 (Uniprot ID: Q13526) interaction with NANOG PEST, we synthesized several peptides encompassing the PEST region (Figure 2). The use of synthetic peptides ensures completely phosphorylated and pure states for S65 and S71. Previous studies have shown that the Pin1 PPIase domain has preferred bias toward the cis Pro conformer.32,33 Thus, we tested whether an increase in the % cis (Pro) conformer in NANOG PEST peptides correlated with an increase in binding affinities to Pin1. Various peptides were synthesized by replacing Pro residues (adjacent to the phosphorylated Ser) with pipecolic acid (pSPip and pSPippSPip), which have been shown to increase the cis population.34 31P NMR spectra (phosphorylated Ser residues) confirm the increase in the cis peaks by ~10–20% (Figure 2).

Figure 2.

Figure 2.

NANOG PEST peptides. Residue compositions and the % cis vs % trans population of the phosphorylated Ser residues preceding Pro as determined from 31P NMR spectroscopy.

To characterize the interaction of Pin1 with NANOG PEST peptides, NMR chemical shift perturbation (CSP) studies were performed by titrating 15N-labeled Pin1 with saturating concentrations of peptides (up to 3–4 mM, Figure 3). Consistent with previous studies of Pin1 and its substrates, we observed minimal shifts with unphosphorylated (SP) or with the pSA, indicating that the specificity of the interaction is due to phosphorylation and proline dependence of Pin1 interaction25 (Figure 3a,b). Serine phosphorylation (pSP or pSPpSP peptides) results in significant backbone chemical shift changes, with most residues affected in the Pin1 WW domain (Figure 3a). Increasing the cis Pro conformers (pSPip and pSPippSPip peptides) dramatically increases the chemical shift changes for residues in the PPIase domain while maintaining similar shift changes in the WW domain. For example, representative 1H–15N NMR HSQC spectral slices (Figure 3c) show hardly any shifts for PPIase residues M130, D153, and S115 and for pSP and pSPpSP peptides but large shifts for the cis-enhanced peptides (pSPip and pSPippSPip). This agrees with previous studies showing Pin1’s PPIase domain’s preference for cis-locked peptides.32,33 More interestingly, our results show that increasing the cis Pro conformers in both sites (pS65 and pS71) results in even larger chemical shifts compared to modification at only one site, suggesting synergistic effects in Pin1 interaction. We determined the specific binding constants from each Pin1 domain (Figure 3d, Table 2). The singly phosphorylated NANOG peptides pSP and pSPip bound with Kd values of 320 ± 100 and 390 ± 120 uM, respectively, to the Pin1 WW domain. We were unable to obtain reliable affinities for SP, pSA (both WW and PPIase domain), pSP, and pSPip (PPIase domain only) peptides because either the chemical shifts were too small (δΔav < 0.05 ppm) or the binding affinities were weak (i.e., no detectable saturation). Doubly phosphorylated (pSPpSP or pSPippSPip) peptides result in 5–6-fold tighter affinity to Pin1 WW domain residues compared to singly pS65 phosphorylated (pSP or pSPip) peptides (Kd ~ 60–70 vs 300–400 μM; Table 2). This suggests that both sites can interact with Pin1 in a bivalent manner, similar to IRAK1 phosphorylated substrates.35 Remarkably, cis Pro isomer enhancement at both sites (even with only a ~10% increase per site) significantly increases the affinity by ~10-fold (Figure 3d,e). Our data suggest that further increasing the cis Pro content, either by substitution to 5,5-dimethylproline (shown to increase by as much as 96% cis)34 or by designing PEST-based cis-locked peptides,33 could potentially result in stronger Pin1 binders that can be integrated in current Pin1-based drug discovery efforts.36-38

Figure 3.

Figure 3.

Enhanced cis NANOG PEST peptides increase Pin1 interaction. (a) Chemical shift perturbations (CSPs) of the various NANOG PEST peptides. Dashed line at δΔav = 0.05 ppm represents cutoff for significant chemical shift changes. (b) Mapping of the chemical shift changes (δΔav > 0.05 ppm) on the surface of Pin1 structure. (c) 15N-HSQC 15N Pin1 spectra (selected regions) upon titration with different concentrations of NANOG PEST peptides (pSP, pSPpSP, pSPip, pSPippSPip; top to bottom panels, respectively). The selected peaks are representative residue markers for the WW domain (W34HE1, left) and PPIase domain (M130, D153; middle panels, and S115; right panels). (d) Representative binding curves (WW domain, top; PPIase domain, bottom) for the interaction of Pin1 with different NANOG peptides. (e) Box plots (median line and 10–90 percentile range are shown) for the dissociation constants obtained from representative residues (see Table 2 for Kd and the residues; ns = not significant; p values are presented in the graph).

Table 2.

Binding Affinities of Pin1 with Different NANOG PEST Peptides (Reported Values Are in μM)

peptide WW PPIaseb
pSPpSP 70 ± 80a 1200 ± 1000c
pSPippSPip 60 ± 40a 16 ± 30c
pSP 390 ± 120b ndd
pSPip 320 ± 100b nd
SP nd nd
pSA nd nd
a

ave and stdev from eight peaks: S16N, Y23N, F25H, S32N, Q33H, W34N, W34HE1, E35N.

b

ave and stdev from nine peaks: S16N, G20N, R21H, Y23N, F25H, S32N, W34N, W34HE1, E35N.

c

ave and stdev from nine residues: S67N, S72N, S115H, M130H, K132H, D153H, S154N (M130N and D153N for pSPpSP).

d

nd, not determined.

NANOG expression is implicated in the generation of cancer stem cells (CSC) and progression of cancers.39-47 NANOG dosage correlates with increased metastasis and invasion of ovarian and breast cancer cells46,48 and with castration-resistant tumor growth and regeneration in prostate cancer.43 A previous study showed that disruption of Pin1-NANOG interaction inhibits cell stemness.6 Our study demonstrates that specific NANOG PEST cis Pro-based peptides are potential inhibitors for preventing Pin1-dependent NANOG stabilization and mitigating CSC formation and cancer progression and recurrence.

Supplementary Material

SI

ACKNOWLEDGMENTS

This work was supported by grants from the NIH (R01 GM122763) and the Welch Foundation (Q-2097-20220331) to J.C.F. A.C.M.F. is supported by NIH grant R01 NS105874.

Footnotes

Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.biochem.4c00056.

Materials, methods, and mass spectrometry data for the peptides (PDF)

Accession Codes

NANOG: Q9H9S0. PIN1: Q13526. BMRB ACCESSION ID 52388 and 52389.

The authors declare no competing financial interest.

Contributor Information

Josephine C. Ferreon, Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States.

Hai Minh Ta, Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States.

Hyosuk Yun, Department of Chemistry, Chonnam National University, Gwangju 61186, Republic of Korea.

Kyoung-Jae Choi, Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States.

My Diem Quan, Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States.

Phoebe S. Tsoi, Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States

Choel Kim, Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States.

Chul Won Lee, Department of Chemistry, Chonnam National University, Gwangju 61186, Republic of Korea.

Allan Chris M. Ferreon, Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, Texas 77030, United States.

REFERENCES

  • (1).Chambers I; Silva J; Colby D; Nichols J; Nijmeijer B; Robertson M; Vrana J; Jones K; Grotewold L; Smith A Nanog safeguards pluripotency and mediates germline development. Nature 2007, 450, 1230–1234. [DOI] [PubMed] [Google Scholar]
  • (2).Silva J; Nichols J; Theunissen TW; Guo G; van Oosten AL; Barrandon O; Wray J; Yamanaka S; Chambers I; Smith A Nanog is the gateway to the pluripotent ground state. Cell 2009, 138, 722–737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (3).Boyer LA; Lee TI; Cole MF; Johnstone SE; Levine SS; Zucker JP; Guenther MG; Kumar RM; Murray HL; Jenner RG; Gifford DK; Melton DA; Jaenisch R; Young RA Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005, 122, 947–956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (4).Sharma R; Choi KJ; Quan MD; Sharma S; Sankaran B; Park H; LaGrone A; Kim JJ; MacKenzie KR; Ferreon ACM; Kim C; Ferreon JC Liquid condensation of reprogramming factor KLF4 with DNA provides a mechanism for chromatin organization. Nat. Commun 2021, 12, 5579. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (5).Choi KJ; Quan MD; Qi C; Lee JH; Tsoi PS; Zahabiyon M; Bajic A; Hu L; Prasad BVV; Liao SJ; Li W; Ferreon ACM; Ferreon JC NANOG prion-like assembly mediates DNA bridging to facilitate chromatin reorganization and activation of pluripotency. Nat. Cell Biol 2022, 24, 737–747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (6).Moretto-Zita M; Jin H; Shen Z; Zhao T; Briggs SP; Xu Y Phosphorylation stabilizes Nanog by promoting its interaction with Pin1. Proc. Natl. Acad. Sci. U. S. A 2010, 107, 13312–13317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (7).Brumbaugh J; Russell JD; Yu P; Westphall MS; Coon JJ; Thomson JA NANOG is multiply phosphorylated and directly modified by ERK2 and CDK1 in vitro. Stem Cell Reports 2014, 2, 18–25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (8).Ramakrishna S; Suresh B; Lim KH; Cha BH; Lee SH; Kim KS; Baek KH PEST motif sequence regulating human NANOG for proteasomal degradation. Stem cells and development 2011, 20, 1511–1519. [DOI] [PubMed] [Google Scholar]
  • (9).Rogers S; Wells R; Rechsteiner M Amino acid sequences common to rapidly degraded proteins: the PEST hypothesis. Science 1986, 234, 364–368. [DOI] [PubMed] [Google Scholar]
  • (10).Kim SH; Kim MO; Cho YY; Yao K; Kim DJ; Jeong CH; Yu DH; Bae KB; Cho EJ; Jung SK; Lee MH; Chen H; Kim JY; Bode AM; Dong Z ERK1 phosphorylates Nanog to regulate protein stability and stem cell self-renewal. Stem Cell Res. 2014, 13, 1–11. [DOI] [PubMed] [Google Scholar]
  • (11).Kops O; Zhou XZ; Lu KP Pin1 modulates the dephosphorylation of the RNA polymerase II C-terminal domain by yeast Fcp1. FEBS Lett. 2002, 513, 305–311. [DOI] [PubMed] [Google Scholar]
  • (12).Liou YC; Ryo A; Huang HK; Lu PJ; Bronson R; Fujimori F; Uchida T; Hunter T; Lu KP Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes. Proc. Natl. Acad. Sci. U. S. A 2002, 99, 1335–1340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (13).Liu W; Youn HD; Zhou XZ; Lu KP; Liu JO Binding and regulation of the transcription factor NFAT by the peptidyl prolyl cis-trans isomerase Pin1. FEBS Lett. 2001, 496, 105–108. [DOI] [PubMed] [Google Scholar]
  • (14).Lu KP Phosphorylation-dependent prolyl isomerization: a novel cell cycle regulatory mechanism. Prog. Cell Cycle Res 4 2000, 83–96. [DOI] [PubMed] [Google Scholar]
  • (15).Ping Lu K; Hanes SD; Hunter T A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 1996, 380, 544–547. [DOI] [PubMed] [Google Scholar]
  • (16).Nishi M; Akutsu H; Masui S; Kondo A; Nagashima Y; Kimura H; Perrem K; Shigeri Y; Toyoda M; Okayama A; Hirano H; Umezawa A; Yamamoto N; Lee SW; Ryo A A distinct role for Pin1 in the induction and maintenance of pluripotency. J. Biol. Chem 2011, 286, 11593–11603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (17).Ranganathan R; Lu KP; Hunter T; Noel JP Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent. Cell 1997, 89, 875–886. [DOI] [PubMed] [Google Scholar]
  • (18).Ryo A; Liou YC; Wulf G; Nakamura M; Lee SW; Lu KP PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells. Mol. Cell. Biol 2002, 22, 5281–5295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (19).Ryo A; Nakamura M; Wulf G; Liou YC; Lu KP Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat. Cell Biol 2001, 3, 793–801. [DOI] [PubMed] [Google Scholar]
  • (20).Ryo A; Suizu F; Yoshida Y; Perrem K; Liou YC; Wulf G; Rottapel R; Yamaoka S; Lu KP Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol. Cell 2003, 12, 1413–1426. [DOI] [PubMed] [Google Scholar]
  • (21).Schelhorn C; Martin-Malpartida P; Sunol D; Macias MJ Structural Analysis of the Pin1-CPEB1 interaction and its potential role in CPEB1 degradation. Sci. Rep 2015, 5, No. 14990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (22).Shen M; Stukenberg PT; Kirschner MW; Lu KP The essential mitotic peptidyl-prolyl isomerase Pin1 binds and regulates mitosis-specific phosphoproteins. Genes Dev. 1998, 12, 706–720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (23).Wulf GM; Liou YC; Ryo A; Lee SW; Lu KP Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J. Biol. Chem 2002, 277, 47976–47979. [DOI] [PubMed] [Google Scholar]
  • (24).Xu YX; Hirose Y; Zhou XZ; Lu KP; Manley JL Pin1 modulates the structure and function of human RNA polymerase II. Genes Dev. 2003, 17, 2765–2776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (25).Yaffe MB; Schutkowski M; Shen M; Zhou XZ; Stukenberg PT; Rahfeld JU; Xu J; Kuang J; Kirschner MW; Fischer G; Cantley LC; Lu KP Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science 1997, 278, 1957–1960. [DOI] [PubMed] [Google Scholar]
  • (26).Zheng H; You H; Zhou XZ; Murray SA; Uchida T; Wulf G; Gu L; Tang X; Lu KP; Xiao Z-X The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 2002, 419, 849–852. [DOI] [PubMed] [Google Scholar]
  • (27).Zhou XZ; Kops O; Werner A; Lu PJ; Shen M; Stoller G; Kullertz G; Stark M; Fischer G; Lu KP Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol. Cell 2000, 6, 873–883. [DOI] [PubMed] [Google Scholar]
  • (28).Dayhoff GW, 2nd; Uversky, V. N. Rapid prediction and analysis of protein intrinsic disorder. Protein Sci. 2022, 31, No. e4496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (29).Varadi M; Anyango S; Deshpande M; Nair S; Natassia C; Yordanova G; Yuan D; Stroe O; Wood G; Laydon A; Zidek A; Green T; Tunyasuvunakool K; Petersen S; Jumper J; Clancy E; Green R; Vora A; Lutfi M; Figurnov M; Cowie A; Hobbs N; Kohli P; Kleywegt G; Birney E; Hassabis D; Velankar S AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 2022, 50, D439–D444. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (30).Jumper J; Evans R; Pritzel A; Green T; Figurnov M; Ronneberger O; Tunyasuvunakool K; Bates R; Zidek A; Potapenko A; Bridgland A; Meyer C; Kohl SAA; Ballard AJ; Cowie A; Romera-Paredes B; Nikolov S; Jain R; Adler J; Back T; Petersen S; Reiman D; Clancy E; Zielinski M; Steinegger M; Pacholska M; Berghammer T; Bodenstein S; Silver D; Vinyals O; Senior AW; Kavukcuoglu K; Kohli P; Hassabis D Highly accurate protein structure prediction with AlphaFold. Nature 2021, 596, 583–589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (31).Schwarzinger S; Kroon GJ; Foss TR; Chung J; Wright PE; Dyson HJ Sequence-dependent correction of random coil NMR chemical shifts. J. Am. Chem. Soc 2001, 123, 2970–2978. [DOI] [PubMed] [Google Scholar]
  • (32).Namanja AT; Wang XJ; Xu B; Mercedes-Camacho AY; Wilson KA; Etzkorn FA; Peng JW Stereospecific gating of functional motions in Pin1. Proc. Natl. Acad. Sci. U. S. A 2011, 108, 12289–12294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (33).Wang XJ; Xu B; Mullins AB; Neiler FK; Etzkorn FA Conformationally locked isostere of phosphoSer-cis-Pro inhibits Pin1 23-fold better than phosphoSer-trans-Pro isostere. J. Am. Chem. Soc 2004, 126, 15533–15542. [DOI] [PubMed] [Google Scholar]
  • (34).Nakamura K; Greenwood A; Binder L; Bigio EH; Denial S; Nicholson L; Zhou XZ; Lu KP Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer’s disease. Cell 2012, 149, 232–244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (35).Rogals MJ; Greenwood AI; Kwon J; Lu KP; Nicholson LK Neighboring phosphoSer-Pro motifs in the undefined domain of IRAK1 impart bivalent advantage for Pin1 binding. FEBS J. 2016, 283, 4528–4548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (36).Pinch BJ; Doctor ZM; Nabet B; Browne CM; Seo HS; Mohardt ML; Kozono S; Lian X; Manz TD; Chun Y; Kibe S; Zaidman D; Daitchman D; Yeoh ZC; Vangos NE; Geffken EA; Tan L; Ficarro SB; London N; Marto JA; Buratowski S; Dhe-Paganon S; Zhou XZ; Lu KP; Gray NS Identification of a potent and selective covalent Pin1 inhibitor. Nat. Chem. Biol 2020, 16, 979–987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (37).Dubiella C; Pinch BJ; Koikawa K; Zaidman D; Poon E; Manz TD; Nabet B; He S; Resnick E; Rogel A; Langer EM; Daniel CJ; Seo HS; Chen Y; Adelmant G; Sharifzadeh S; Ficarro SB; Jamin Y; Martins da Costa B; Zimmerman MW; Lian X; Kibe S; Kozono S; Doctor ZM; Browne CM; Yang A; Stoler-Barak L; Shah RB; Vangos NE; Geffken EA; Oren R; Koide E; Sidi S; Shulman Z; Wang C; Marto JA; Dhe-Paganon S; Look T; Zhou XZ; Lu KP; Sears RC; Chesler L; Gray NS; London N Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo. Nat. Chem. Biol 2021, 17, 954–963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (38).Liu L; Zhu R; Li J; Pei Y; Wang S; Xu P; Wang M; Wen Y; Zhang H; Du D; Ding H; Jiang H; Chen K; Zhou B; Yu L; Luo C Computational and Structure-Based Development of High Potent Cell-Active Covalent Inhibitor Targeting the Peptidyl-Prolyl Isomerase NIMA-Interacting-1 (Pin1). J. Med. Chem 2022, 65, 2174–2190. [DOI] [PubMed] [Google Scholar]
  • (39).Amsterdam A; Raanan C; Schreiber L; Polin N; Givol D LGR5 and Nanog identify stem cell signature of pancreas beta cells which initiate pancreatic cancer. Biochem. Biophys. Res. Commun 2013, 433, 157–162. [DOI] [PubMed] [Google Scholar]
  • (40).Arif K; Hussain I; Rea C; El-Sheemy M The role of Nanog expression in tamoxifen-resistant breast cancer cells. Onco Targets Ther 2015, 8, 1327–1334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (41).Bais MV; Shabin ZM; Young M; Einhorn TA; Kotton DN; Gerstnefeld LC Role of Nanog in the maintenance of marrow stromal stem cells during post natal bone regeneration. Biochem. Biophys. Res. Commun 2012, 417, 211–216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (42).Chiou SH; Yu CC; Huang CY; Lin SC; Liu CJ; Tsai TH; Chou SH; Chien CS; Ku HH; Lo JF Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin. Cancer Res 2008, 14, 4085–4095. [DOI] [PubMed] [Google Scholar]
  • (43).Jeter CR; Liu B; Liu X; Chen X; Liu C; Calhoun-Davis T; Repass J; Zaehres H; Shen JJ; Tang DG NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene 2011, 30, 3833–3845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (44).Kregel S; Szmulewitz RZ; Vander Griend DJ The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells. Prostate 2014, 74, 1530–1543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (45).Riggi N; Suva ML; De Vito C; Provero P; Stehle JC; Baumer K; Cironi L; Janiszewska M; Petricevic T; Suva D; Tercier S; Joseph JM; Guillou L; Stamenkovic I EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes Dev. 2010, 24, 916–932. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (46).Siu MK; Wong ES; Kong DS; Chan HY; Jiang L; Wong OG; Lam EW; Chan KK; Ngan HY; Le XF; Cheung AN Stem cell transcription factor NANOG controls cell migration and invasion via dysregulation of E-cadherin and FoxJ1 and contributes to adverse clinical outcome in ovarian cancers. Oncogene 2013, 32, 3500–3509. [DOI] [PubMed] [Google Scholar]
  • (47).Wang ML; Chiou SH; Wu CW Targeting cancer stem cells: emerging role of Nanog transcription factor. Onco Targets Ther 2013, 6, 1207–1220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (48).Lu X; Mazur SJ; Lin T; Appella E; Xu Y The pluripotency factor nanog promotes breast cancer tumorigenesis and metastasis. Oncogene 2014, 33, 2655–2664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (49).Li X; Romero P; Rani M; Dunker AK; Obradovic Z Predicting Protein Disorder for N-, C-, and Internal Regions. Genome Inform Ser. Workshop Genome Inform 1999, 10, 30–40. [PubMed] [Google Scholar]
  • (50).Radivojac P; Obradovic Z; Brown CJ; Dunker AK Prediction of boundaries between intrinsically ordered and disordered protein regions. Pac Symp. Biocomput 2003, 216–227. [PubMed] [Google Scholar]
  • (51).Peng K; Radivojac P; Vucetic S; Dunker AK; Obradovic Z Length-dependent prediction of protein intrinsic disorder. BMC Bioinformatics 2006, 7, 208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • (52).Dosztanyi Z; Csizmok V; Tompa P; Simon I The pairwise energy content estimated from amino acid composition discriminates between folded and intrinsically unstructured proteins. J. Mol. Biol 2005, 347, 827–839. [DOI] [PubMed] [Google Scholar]
  • (53).Xue B; Dunbrack RL; Williams RW; Dunker AK; Uversky VN PONDR-FIT: a meta-predictor of intrinsically disordered amino acids. Biochim. Biophys. Acta 2010, 1804, 996–1010. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

SI

RESOURCES